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Abstract: Denosumab is a fully human monoclonal antibody to the receptor activator of 
nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfam-
ily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, 
and reversible reduction in bone turnover markers, a continuous marked increase in bone min-
eral density at all sites, and a marked decrease in the risk of vertebral, hip, and nonvertebral 
fractures in women with postmenopausal osteoporosis. Therefore, it could be considered as 
an effective alternative to previous bisphosphonate treatment as well as first-line treatment of 
severe osteoporosis. Cost-effectiveness studies support this suggestion. In addition, denosumab 
seems to be the safest treatment option in patients with impaired renal function. Denosumab 
is characterized by reversibility of its effect after treatment discontinuation, in contrast with 
bisphosphonates. Large-scale clinical trials, including the extension of FREEDOM trial for up 
to 5 years, are reassuring for its safety. However, given its brief post-market period, vigilance 
regarding adverse events related to putative RANKL inhibition in tissues other than bone, as 
well as those related to bone turnover oversuppression, is advised.
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Introduction
Osteoporosis is the most common bone disease, caused by a relatively increased rate of 
bone resorption by osteoclasts that exceeds the rate of bone formation by osteoblasts, 
resulting in net loss of bone mass. Osteoporosis affects a significant proportion of 
postmenopausal women and its incidence increases with advancing age.1 Consider-
ing that the mean age of menopause is around 50 years and the life expectancy for 
women is currently over 80 years in Western countries (http://en.wikipedia.org/wiki/
List_of_countries_by_life_expectancy) and continues to grow, many women are going 
to spend a long period of their lives being postmenopausal and potentially osteoporotic. 
Therefore, the need for antiosteoporotic agents that can be administered for prolonged 
periods of time with both efficacy and safety is mandatory.
Unfortunately, many currently available treatments have a limited duration of safe 
administration in humans. For example, anabolic agents, such as teriparatide, the 1–34 
amino-terminal fraction of natural parathyroid hormone, and synthetic parathyroid 
hormone 1–84 are given for a maximum of two years. Prolonged administration 
of bisphosphonates, currently representing the medications most commonly used 
for osteoporosis, has raised concerns about rare but serious adverse events, such as 
osteonecrosis of the jaw, atypical fractures, and esophageal cancer.2 Therefore, a drug 
holiday after 5–10 years of bisphosphonate treatment is advised.2 Thus, a medication 
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that could safely treat osteoporosis in the long term would 
be welcome. Could denosumab, an antibody against human 
RANKL, be that medication?
Denosumab
The receptor activator of nuclear factor-κB ligand (RANKL) 
is a member of the tumor necrosis factor (TNF) receptor 
superfamily, essential for osteoclastogenesis. RANKL is 
expressed by activated T cells and B cells, marrow stromal 
cells, osteoblasts, lining cells, osteocytes, and chondrocytes. 
Alternative splicing of RANKL mRNA allows expression 
of a type II transmembrane glycoprotein or a soluble ligand. 
  Soluble RANKL can also be released from its membrane-
bound state by metalloproteinases. RANKL binds to its 
receptor, RANK, on the surface of osteoclast precursors and 
enhances their differentiation, survival, and fusion, while acti-
vating mature osteoclasts and inhibiting their apoptosis. The 
natural compensatory mechanism against RANKL is another 
member of the TNF receptor superfamily,   osteoprotegerin, 
a decoy receptor, produced locally in the bone microenvi-
ronment by mature osteoblasts.3 Osteoprotegerin binds to 
RANKL, thereby blocking the RANKL-RANK interaction 
and thus osteoclast differentiation and activation.4
Derangement of the balance in RANKL/osteoprotegerin 
action is implicated in the pathophysiology of metabolic 
bone diseases, including osteoporosis,5 and several current 
  antiosteoporotic therapies are thought to act, at least in 
part, through modification of the RANKL/osteoprotegerin 
  expression.5 Denosumab (AMG-162) is a fully human 
  monoclonal IgG2 antibody against human RANKL that 
  specifically binds and neutralizes RANKL in order to 
decrease bone resorption and subsequent bone loss.
Pharmacology, mode of action,  
and pharmacokinetics
Denosumab is composed of amino acids and carbohydrates 
as natural immunoglobulin and its stereotactic configuration 
resembles that of the natural IgG2 immunoglobulin. Limited 
pharmacokinetic/pharmacodynamic analyses of denosumab 
using noncompartmental approaches have been reported. 
Because rodent RANKL is not recognized by this drug, 
preclinical data have been limited to studies conducted in 
cynomolgus monkeys.6
Pharmacodynamics
Denosumab binds to RANKL with high specificity and affin-
ity (Kd approximately 10–12 M).6 Therefore, it is more potent 
and acts for longer than natural osteoprotegerin or even the 
initially tested recombinant osteoprotegerin or RANK mol-
ecules that were constructed by removing different domains 
of the molecule and fusing the remaining peptide to the Fc 
domain of human immunoglobulin G1 (osteoprotegerin-Fc, 
Fc-osteoprotegerin, RANK-Fc).7–10 The result is a more 
prolonged suppression of osteoclasts.11,12 Another limitation 
of the abovementioned recombinant molecules has been a 
lack of specificity for RANKL (they also react with other 
members of the TNF family, including TNF-related apopto-
sis-inducing ligand [TRAIL]) which seems to be overcome 
with denosumab.
The effect of denosumab appears to be primarily antire-
sorptive. A single subcutaneous dose of denosumab results 
in a dose-dependent, rapid (within 12 hours), profound (up 
to 84%), and sustained (up to 6 months) decrease in bone 
resorption markers (N-telopeptide and C-telopeptide of type 1 
collagen) and a subsequent decrease in bone formation mark-
ers (bone-specific alkaline phosphatase and N-propeptide 
of procollagen type 1) due to a coupling effect, leading to 
a decrease in bone turnover.11–13 Decreases in bone-specific 
alkaline phosphatase occur later and are less pronounced 
than for N-telopeptide.11 The decreases are maximal at 
three months (70%–90% for resorption and 55%–75% 
for formation markers) and remain for as long as treat-
ment is continued.5,14 After discontinuation of denosumab, 
bone markers rise to above pretreatment levels14–16 within 
12 months. Levels of the markers return towards baseline 
in the second year of discontinuation, even with no further 
therapy.16 The rebound rise of bone markers above baseline 
after cessation of denosumab is similar to the pattern seen 
after cessation of estrogen therapy, although rebound occurs 
earlier with denosumab. The implication of this rebound 
effect on clinical outcomes is not clear.
Differences  in  the  level  and  pattern  of  serum 
collagen type 1 C-telopeptide decreases have been observed 
between denosumab and alendronate, that are possibly due to the 
distinct mechanisms by which the two agents inhibit bone 
resorption.12,13
Following injection of denosumab, albumin-adjusted 
serum calcium levels decrease in a dose-dependent manner. 
The decrease is early but modest (does not exceed 10%). 
Serum phosphate levels also decrease in a manner similar 
to that of calcium because of the antiresorptive effect of 
denosumab. Intact parathyroid hormone levels increase up to 
three-fold after a few days and slowly return towards baseline 
after several months.11
The denosumab dose for treatment of osteoporosis 
in adults is 60 mg subcutaneously once every 6 months. 
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A 60 mg dose provides RANKL inhibition similar to that 
achieved by equivalent body-weight-based dosing; there-
fore, there seems to be no need for dose adjustment based 
on patient demographics. The effects of age and race on 
the area under the serum concentration-time curve for 
denosumab were less than 15% over the range of covariate 
values evaluated.17 Administration of denosumab does not 
require adjustment in patients with renal impairment, and 
its use in patients with severe hepatic impairment has not 
been studied.18,19
To maintain the stability and pharmaceutical activity 
of denosumab, the drug must be stored protected from 
direct light and exposure to temperatures 25°C, usually 
at 2°C–8°C but not under 0°C, and definitely used within 
14 days after removal from the refrigerator. Vigorous treat-
ment and shaking should be avoided.18
Pharmacokinetics
The pharmacokinetics of subcutaneously administered deno-
sumab in postmenopausal women are nonlinear with dose,11,20 
and because of this, the mean serum residence time increases 
with dose from 12 to 46 days. The nonlinearity in denosumab 
pharmacokinetics is probably due to RANKL binding.17
Specifically, three distinct phases have been observed,11 
ie, a prolonged absorption phase, which results in maximum 
serum concentration (Cmax) in 5–21 days after administration, 
with the Cmax to increase disproportionally (2.6-fold larger) 
to the increase in dose, and be reached in approximately 10 
days at the 60 mg dose;18 a prolonged β-phase, characterized 
by dose-dependent increases in the half-life to a maximum 
of 32 days, with the half-life of a 60 mg subcutaneous 
dose of denosumab being approximately 25–32 days;18 
and a more rapid terminal phase, evident at concentra-
tions ,1000 ng/mL, with a dose-dependent increase in half-
life from 5 to 10 days.
The bioavailability of denosumab after subcutaneous 
administration has been reported to be 61%–64%,17,21 with 
a k(a) of 0.00883 h-1. The baseline RANKL level, quasi-
steady-state constant and RANKL degradation rate were 
614 ng/mL, 138 ng/mL, and 0.00148 h-1, respectively.17
Characterization of other monoclonal antibodies indicates 
that absorption is probably mediated by the lymphatic system 
and that clearance may occur via the reticuloendothelial sys-
tem because renal excretion is not expected.22,23 The central 
volume of distribution and linear clearance are 2.49 L/66 kg 
and 3.06 mL/hour/66 kg, respectively.17
In conclusion, osteoclastic activity is profoundly sup-
pressed while denosumab is in the circulation, which is for 
a prolonged period based on its pharmacokinetic profile. 
However, this effect is reversible,11,24 as indicated by the 
return of N-telopeptide levels to baseline when denosumab 
is cleared from the circulation.11
Efficacy in postmenopausal 
osteoporosis
Preclinical studies
Denosumab inhibited bone resorption and increased bone 
density in knock-in mice that expressed chimeric (murine/
human) RANKL.25 In ovariectomized primates, denosumab 
significantly increased cortical and trabecular bone mineral 
content and bone mineral density (BMD) and improved 
biomechanical parameters of bone strength.26,27
Clinical studies
As mentioned above, subcutaneous administration of deno-
sumab every 6 months has led to rapid and remarkable 
decreases in bone turnover markers, which are at least com-
parable with the most potent bisphosphonates28 and remain 
for as long as treatment is continued.5,29,30 These decreases 
result in a significant increase in BMD at both predominantly 
trabecular and predominantly cortical sites and a consequent 
reduction in fracture risk30,31 (Table 1).
In particular, BMD continues to increase as long as 
treatment is continued, for at least up to 5–6 years.14,30 Data 
from the FREEDOM (Fracture Reduction Evaluation of 
  Denosumab in Osteoporosis every 6 Months) trial, a three-year 
Phase III study of the effect of denosumab in   postmenopausal 
women with osteoporosis, showed significant increases 
in BMD at the lumbar spine, hip, and distal radius.31 The 
mean increase in lumbar spine BMD in the denosumab tri-
als ranged between 3.0%–5.3% at 12 months, 6.5%–7.7% 
at 24 months, and 8.2%–10.1% at 36 months of treatment. 
The mean increase in total hip BMD was 1.6%–3.6% at 
12 months, 3.4%–5.1% at 24 months, and 5.2%–6.7% at 
36 months.31 The mean increase in distal radius BMD was 
1.1%–1.3% at 12 months13,32 and 0.3%–1.4% at 24 months, 
compared with a 2.1% reduction in the placebo group.30,33 
These increases are significantly greater when compared 
directly with those achieved with alendronate13 and at least 
similar when compared indirectly with those achieved with 
other bisphosphonates.28
The extension of the FREEDOM trial is currently ongoing 
in an open-label design for an additional 7 years, for a total 
of 10 years, aiming to evaluate the long-term efficacy and 
safety of denosumab. Data from the first 2 years of the exten-
sion trial were recently published.30 According to these data, 
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  during years 4 and 5 of treatment, BMD increased further at 
all sites (by 1.9% and 1.6%, respectively, at the lumbar spine; 
by 0.8% and 0.6%, respectively, at the total hip; by 0.9% 
and 0.4%, respectively, at the femoral neck; and by 0.6% 
and −0.3%, respectively, at the distal radius).30 The total 
increase in BMD over the 5 years of continuous treatment 
reached 13.7% in the lumbar spine, 7.0% in the total hip, 6.1% 
in the femoral neck, and 2.3% in the distal radius.30
Discontinuation of denosumab results in loss of gains 
in BMD; in both the Phase III33 and Phase II15 trials, BMD 
at the spine and total hip returned to pretreatment levels 
within 12 months of discontinuation. Surprisingly, in the 
Phase II trial, BMD remained below baseline for a further 
12 months in those who remained off treatment, and then 
returned to baseline levels at month 36–48 without additional 
medication. In contrast, after one year of retreatment with 
denosumab (following 12 months of discontinuation) BMD 
increased again, and more rapidly than the first time, at both 
the spine and hip to levels comparable with those achieved 
after the first 24 months of treatment.33
In the FREEDOM trial, a significant reduction in both 
vertebral and nonvertebral fractures, at least equal to those 
achieved by bisphosphonates, was observed.31 More specifi-
cally, a reduction by 68% for new vertebral fractures, 20% 
for new nonvertebral fractures, and 40% for hip fractures 
compared with placebo at 36 months was reported. In the 
2-year extension of FREEDOM, fracture incidence rates 
remained low and below those observed in the core trial 
placebo group. They were also below the estimated fracture 
incidence rates of a “virtual untreated twin” cohort (twin-
estimated placebo). More specifically, the annual incidence 
of a new vertebral fracture for years 4 and 5 of treatment was 
1.4% compared with 2.2% for the twin-estimated placebo; the 
annual incidence of a nonvertebral fracture for years 4 and 5 
of treatment was 1.4% and 1.1%, respectively, compared 
with 2.6% for the twin-estimated placebo.
In a recent meta-analysis, denosumab was associated with 
odds ratios of 0.33, 0.50, and 0.74 for vertebral, hip, and 
nonvertebral fractures, respectively, compared with placebo.34 
Treatment with denosumab for over 3 years was associated 
with a 32% decrease in clinical osteoporotic fractures.35
Reduction in fracture risk with denosumab has been 
reported to be independent of age, prior fracture, parental his-
tory of hip fracture, baseline femoral neck BMD, or second-
ary causes of osteoporosis,35 and greater in those at moderate 
to high risk of fracture assessed by FRAX®.35 On the other 
hand, in another analysis of the same study population, the 
reduction in the risk of nonvertebral fracture was statistically 
  significant only in women with a baseline femoral neck BMD 
T-score # −2.5 but not in those with a T-score  −2.5.36,37 
A low body mass index has been associated with greater 
efficacy of denosumab,35,36 and this could be attributed to the 
lower estradiol levels observed in women with lower body 
mass index which result in higher bone turnover and fracture 
risk. Another reason could be the proportionally greater drug 
amount per kilogram, and therefore greater tissue exposure 
of subjects with lower body mass index to denosumab. 
However, this is unlikely, given that the pharmacokinetics 
of denosumab are not notably affected by body weight, as 
evidenced by its consistent pharmacodynamic effect across 
a wide range of weights.35
Furthermore, denosumab is effective among patients with 
impaired kidney function.38 More specifically, the magnitude 
of fracture risk reduction and the increases in both spine and 
hip BMD associated with denosumab treatment seem to be 
unaffected by the level of kidney function, even in patients 
with a moderate to severe decrease in glomerular filtration 
rate.
In a post hoc analysis of the Phase II study of denosumab, 
improved mechanical properties at the proximal femur 
  compared with placebo were observed at 12 and 24 months 
of denosumab treatment using hip structural analysis   software 
to evaluate cross-sectional geometry parameters and derived 
strength indices.39 Even when compared directly with 
alendronate, the effects of denosumab were greater at the 
intertrochanteric and shaft sites.39
Long-term safety and tolerability
Osteoporosis is a chronic condition, so safety and tissue 
specificity are prerequisites for any novel treatment, espe-
cially one that affects molecular signaling pathways.40 This 
is the case for denosumab and it comes as no surprise that 
safety issues have attracted particular attention early in the 
development of the drug.5,28
The safety profile of denosumab can largely be summa-
rized as a putatively increased serious infection risk (those that 
require hospitalization), nonspecific dermatologic reactions 
and hypocalcemia, all of which, among others, are detailed in 
the summary of product characteristics for Prolia®.18 Herein, 
the safety concerns for denosumab will be classified into 
two groups on a pathophysiologic basis, ie, those related to 
suboptimal tissue specificity (otherwise, unsatisfactory selec-
tivity of effect on bone) and refer to concerns about increased 
risk of serious infections, cancers (including breast), eczema 
and nondermatologic reactions,  and vascular calcifications, 
and those related to an “exaggerated” effect on bone tissue, 
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namely oversuppression of bone remodeling, hypocalcemia, 
decreased or delayed fracture healing, and osteonecrosis of 
the jaw (Table 2). Of note, many of the safety issues listed 
above remain hypothetical and, thus, caution and an evidence-
based approach are essential.
To begin with, RANKL and RANK are expressed in cells 
of the immune system, including activated T lymphocytes, B 
cells, and dendritic cells,41,42 and RANK activation by RANKL 
is also essential for the growth of T cells and function of 
dendritic cells,3,43 and is considered to play a key role in the 
development of lymph nodes. RANKL also enhances the 
survival of dendritic cells and antigen presentation, implying 
that inhibition of RANKL by denosumab might alter immune 
function or even cause susceptibility to infections.44 Despite 
ample preclinical (in vitro and in vivo in rodents and monkeys) 
evidence of such an effect, it appears that RANKL pathway 
might have a secondary role within the immune system in 
humans,45 potentially through an effect on the intensity of 
the inflammatory response.46 Corroborating evidence in 
support of a modest effect on the immune system in humans 
may be found in osteoclast-poor osteopetrosis due to absence 
of RANKL, in which individuals did not show any obvious 
defects in immunologic parameters47 and in a Phase I trial of 
denosumab, in which no significant changes in B or T cells 
and lymphocyte counts were noted.11 Using best available 
evidence from a meta-analysis of randomized, placebo-
controlled trials, including the large FREEDOM registration 
trial, it has been suggested that denosumab was associated 
with a borderline increased risk of serious   infections (risk 
ratio 1.25, 95% confidence interval 1.00–1.54) in women with 
postmenopausal osteoporosis when intention-to-treat analysis 
was used,48 and with a nonsignificant risk ratio of 2.1 when 
per protocol analysis was used.49
In a recent post hoc analysis of serious infection risk 
using data from the FREEDOM trial, it was suggested that 
serious adverse events of infections, namely referring to the 
skin infections of erysipelas and cellulitis, events of diver-
ticulitis and other gastrointestinal tract, ear, renal and urinary 
infections, and endocarditis, were numerically higher in the 
denosumab group compared with the placebo group, yet 
the number of events was small. Moreover, no relationship 
was observed between serious adverse events of infections 
and timing of administration or duration of exposure to 
denosumab,46 which may be interpreted as indirect evidence 
against a causal relationship. Finally, the two-year extension 
results from the FREEDOM trial (five years of denosumab 
administration in total for the denosumab group and a cross-
over group with two years of denosumab exposure) indicated 
that infectious events did not increase nor decrease with 
long-term administration of denosumab.
Suboptimal tissue specificity may also raise concerns for 
cancer. In fact, osteoprotegerin binding to TRAIL, which is 
a survival factor for tumor cells, may interfere with a natural 
defense mechanism against tumorigenesis.50,51 However, 
although mimicking the effect of osteoprotegerin in human 
RANKL, denosumab does not bind to human TRAIL. Nota-
bly, expression of RANKL and RANK has been shown in 
mammary cells, along with reduction in tumorigenesis upon 
RANKL inhibition.52 In randomized, placebo-controlled tri-
als comparing denosumab with placebo, numerically more 
cases of neoplasms, including those of the breast, ovary and 
gastrointestinal tract, have been reported in the denosumab 
group compared with placebo by McClung et al32 (1.9% 
versus 0%), Bone et al33 (2.4% versus 0.6%), and in the 
FREEDOM trial31 (4.8% versus 4.2%). However, meta-
analyses of randomized, placebo-controlled trials failed to 
detect a statistically significant difference.28,49 Data from the 
extension of FREEDOM are also reassuring so far.30 Long-
term use of denosumab in a large post-marketing base would 
clarify this putative risk.
Suboptimal tissue specificity may also be the case for 
eczema and allergic skin reactions, including dermati-
tis and rashes. RANKL is expressed in keratinocytes of 
inflamed skin53 and Langerhans cells express RANK. Their 
coordination on the skin epithelium results in activation of 
T regulatory cells and control over contact hypersensitivity 
Table  2  Safety  concerns  in  postmenopausal  women  with 
osteoporosis treated with denosumab
Suboptimal tissue specificity Bone turnover  
oversuppression
SIR Rare Hypocalcemia Rare
Infections:
Urinary, upper  
respiratory,   
gastrointestinal  
tract, ear
Uncommon
Rare
ONJ* Very rare
Rashes/dermatitis 
Eczema
Uncommon
Rare
Delayed fracture  
healing
Controversial
Cataracts Uncommon “Frozen bone” Controversial
Hypercholesterolemia Uncommon Atypical fragility Controversial
Vascular calcifications Controversial
Malignancies Controversial
Notes: Classification was based on the following conventions: common (10%), 
uncommon  (1%–10%),  rare  (0.1%–1%),  very  rare  (,0.1%)  and  controversial 
based on one-year event rates. *Etiopathogenesis not fully elucidated yet and thus 
classification is conventional.
Abbreviations: SIR, serious infection risk, requiring hospitalization or resulting in 
death, (erysipelas, cellulitis); ONJ, osteonecrosis of the jaw.
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and autoimmune response. The deranging effect of RANKL 
inhibition by denosumab could amplify cutaneous allergic 
and inflammatory responses and lead to skin hypersensitiv-
ity. In the FREEDOM trial, a small but significantly higher 
risk of eczema was recorded,31 with a 10.8% combined 
  incidence of eczema, dermatitis, and rashes. In the first 
2 years of FREEDOM extension, rates of skin-related events 
were similar to or lower than those in the denosumab group 
  during the core trial.30
More controversial than the latter issue of tissue speci-
ficity is the effect of denosumab on vascular calcification. 
It is an issue of significant concern, because abdominal 
aortic calcification detected on lateral spine images from a 
bone densitometer was found to predict incident myocar-
dial infarction and stroke in older women.54 In preclinical 
models, it was reported that doses of osteoprotegerin that 
inhibit bone resorption can potently inhibit calcification of 
arteries induced by warfarin or vitamin D treatment55 and 
that RANKL inhibition by denosumab reduced vascular 
calcium deposition in glucocorticoid-induced osteoporosis.56 
In humans, serum osteoprotegerin levels were found to be 
associated with the presence and severity of coronary artery 
disease, suggesting that osteoprotegerin may be involved in 
the progression of coronary artery disease,57,58 cardiovascular 
mortality,59 and the onset of cardiovascular disease,60 findings 
not confirmed in a study of patients with peripheral artery 
disease.61 Of note, hypercholesterolemia, a well established 
risk factor for atherosclerosis and vascular calcification, 
was reported as an adverse event in 7.2% of patients on 
denosumab in the FREEDOM trial. Unfortunately, pharma-
cologic manipulation of osteoprotegerin levels by denosumab 
in humans has not been extensively investigated and no 
evidence regarding this effect on vascular calcification has 
been published to date.
As previously specified, the second class of safety con-
cerns largely results from an exaggerated effect of denosumab 
on bone remodeling. Denosumab is a potent antiosteoclastic 
agent, as documented by the rapid and persistent suppression 
of bone markers after its subcutaneous administration at low 
and even undetectable levels. Hypocalcemia was reported 
as an adverse event in 1.7% of the denosumab group in the 
FREEDOM trial, and more women were reported to have 
a calcium concentration below 8.5 mg/dL compared with 
the placebo arm at the one-month assessment (1.7% versus 
0.4%),31 reflecting the acute effect of denosumab on osteoclast 
functionality. It is worth stating that patients with impaired 
renal function were at an increased risk for this effect. Aside 
from the acute effects, oversuppression of bone turnover, in 
proportion to that reported with potent bisphosphonates,2,62 
might lead to diminished repair and microdamage accumu-
lation due to “frozen bone” and potentially to an increased 
risk of atypical fragility and/or osteonecrosis of the jaw, a 
condition that has never been reported to be associated with 
other pharmaceutical agents, except for bisphosphonates.63 
No cases of atypical fractures have been reported in the tri-
als after continuous administration of denosumab for up to 
5 years.30 On the other hand, although extremely rare, the 
potential risk of osteonecrosis of the jaw is a major concern 
in patients treated with denosumab.64,65 Apart from several 
reports of denosumab-related osteonecrosis of the jaw in 
the literature, a pooled analysis in cancer patients with bone 
metastases quantified denosumab-related osteonecrosis of the 
jaw with a similar incidence (1.5%) to that of zoledronic acid66 
and calculated the number needed-to-harm at approximately 
70. In the recent FREEDOM extension trial, two patients with 
osteoporosis from the crossover group (0.09%) but none from 
the long-term denosumab group have been reported as cases 
of osteonecrosis of the jaw.30 Interestingly, these cases were 
not cancer patients and were treated with denosumab for less 
than two years. Overall, it appears that the attributable risk 
is extremely low, at least for patients with osteoporosis. It is 
worth stating that the pathogenesis of osteonecrosis of the jaw 
is not straightforward, and several hypotheses, implicating 
also a role of macrophages,67 vascularity, and bacterial infec-
tion of the area have been proposed. Furthermore, denosumab 
discontinuation is reported to restore bone markers rapidly to 
pretreatment levels, while in both the FREEDOM trial31 and 
its two-year extension,30 the increases in bone markers at the 
end of the dosing interval appeared to increase with time in 
the study. Thus, osteonecrosis of the jaw cannot be classified 
with certainty into the “exaggerated” bone remodeling effect 
or “suboptimal tissue specificity” class.
This is not the case for the concern regarding the effect 
of denosumab on fracture healing, a concern that was 
raised early in the development of pharmacologic RANKL 
inhibition. The question concerning whether coupling and 
osteoclast depletion via RANK blockade would affect cal-
lus formation and maturation and matrix remodeling was 
tested early using RANK-Fc therapy in mice, and no adverse 
effects on fracture healing were observed when therapy was 
discontinued.68 These findings were confirmed in a study 
in which RANK-Fc administration did not adversely affect 
the mechanical properties of healing bone in mice with 
osteogenesis imperfecta and was associated with increased 
strength in wild-type mice.69 In osteoprotegerin-deficient 
mice, accelerated cartilage resorption by chondroclasts was 
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observed during bone fracture healing.70 Finally, denosumab 
was found to delay removal of cartilage and remodeling of the 
fracture callus without diminishing the mechanical integrity 
and stiffness in male human-RANKL knock-in mice.71 Simi-
larly, in a subset of 199 patients with incident nonvertebral 
fractures from the FREEDOM trial, use of denosumab was 
not associated with delayed healing or with any complications 
following fracture surgical management.72 To our knowledge, 
there are no studies on denosumab and implant fixation (ie, 
osseointegration) to date.
In summary, it appears that denosumab is a rather safe 
choice for all subgroups of patients with postmenopausal 
osteoporosis, with the exception of those with chronic kidney 
disease stage 5 and hepatic dysfunction. However, given the 
lack of pharmacovigilance data for this agent as yet64,73 and its 
brief post-marketing presence, it would be prudent to be vigi-
lant for issues relevant to “suboptimal tissue specificity” as 
well as those regarding “bone turnover oversuppression”.
Place in osteoporosis treatment
As mentioned before, denosumab is an antiresorptive com-
pound with anti-fracture efficacy at all skeletal sites and, 
although direct comparative studies with fracture endpoints 
are lacking, completed trials with established surrogates 
suggest an effect at least similar to that of zoledronic acid. 
Therefore, it could be used as first-line antiresorptive treat-
ment in patients with severe newly diagnosed osteoporosis. 
However, it is likely that most patients with severe osteopo-
rosis have already been treated with another antiresorptive 
agent; thus, denosumab could be considered in cases of previ-
ous antiresorptive treatment failure. Additionally, denosumab 
could be used as an alternative treatment option in patients 
with intolerance of oral bisphosphonates. Furthermore, 
given that osteoporosis is a chronic condition, and prolonged 
administration of bisphosphonates has raised concerns about 
rare but serious adverse events limiting their safe use at 5–10 
years,2 denosumab represents an alternative with the potential 
for more prolonged administration than bisphosphonates, 
even if they are effective and well tolerated. Finally, given 
that antiresorptive treatment following parathyroid hormone 
(teriparatide [PTH 1-34] or full-length PTH 1-84) treatment74 
preserves or further increases BMD, denosumab could be 
used sequential to synthetic parathyroid hormone.
The cost-effectiveness of denosumab has been evaluated 
by estimating the cost per quality-adjusted life-year gained. 
Analyses have shown that denosumab is cost-effective in 
postmenopausal women with low bone mass compared with 
no treatment75 or treatment with oral bisphosphonates,76 and 
therefore has the potential to be a first-line treatment for 
postmenopausal women with osteoporosis. As expected, the 
cost-effectiveness of denosumab is favorable, particularly in 
patients at high risk of fracture or with low expected adher-
ence to oral treatments.77
Although both denosumab and bisphosphonates share 
a similar effect on bone turnover, namely interference with 
the osteoclast and suppression of bone resorption, there are 
certain characteristics that clearly separate denosumab from 
the bisphosphonates. First, denosumab represents a distinct 
class of antiresorptives because it inhibits osteoclast matura-
tion in the early stages of development and osteoclast activ-
ity, rather than impairing viability of osteoclasts. Second, it 
is not incorporated into bone mineral. Therefore, the mode 
of action of denosumab is mainly characterized by revers-
ibility of its effect after cessation of treatment, in contrast 
with bisphosphonates which can exert an antifracture effect 
for several years after their discontinuation.78 This could be 
regarded as a disadvantage in terms of rapid BMD reduction 
and putative fracture risk increase after discontinuation of 
denosumab, rendering a drug holiday prohibitive; on the other 
hand, the same characteristic could be an asset in patients at 
risk for bone turnover oversuppression and its consequences 
(atypical fractures, osteonecrosis of the jaw) due to long-term 
antiresorptive treatment. Third, denosumab is metabolized 
via the reticuloendothelial system and not through the kid-
neys. Thus, no adjustment is required in subjects with renal 
impairment, although there is a greater risk of hypocalcemia 
among patients with severe renal insufficiency (creatinine 
clearance ,30 mL/minute) and those on hemodialysis. 
Therefore, in patients with severe kidney dysfunction, par-
ticular attention should be paid to ensuring that patients are 
calcium-replete and vitamin D-replete prior to treatment 
initiation and supplementing with calcium and vitamin D 
during treatment. In addition, patients with severe kidney 
disease may also have metabolic bone diseases that mimic 
osteoporosis clinically but be other forms of renal bone dis-
ease (renal osteodystrophy), where a different management 
strategy may be required. Finally, gastrointestinal side effects, 
one of the most common causes for poor compliance with 
oral bisphosphonates, are lacking with denosumab.79
A practical advantage of denosumab over current thera-
pies is its convenient biannual administration. Thus, deno-
sumab has a likelihood of long-term adherence similar to 
that of the intravenous bisphosphonates. 
Because of the risk of decreased concentrations of serum 
calcium, denosumab is contraindicated in patients with 
hypocalcemia.19 Therefore, careful monitoring is required 
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in patients at high risk of hypocalcemia, such as those with 
hypoparathyroidism   (primary or post-surgical) or malab-
sorption syndromes. Prior to starting denosumab, patients 
with hypocalcemia must have their calcium levels corrected 
because they could severely worsen with denosumab, par-
ticularly in case of concomitant renal impairment.
Comprehensive assessment of the immune status of 
patients on denosumab (white cell count, and T cell, B cell, 
and natural killer cell numbers)80 as well as comparison of 
patients versus controls regarding infections in the   FREEDOM 
study revealed no alarming side effects of   denosumab. 
With both the reported increased risk of infections requir-
ing hospitalization32 and biologic plausibility (inhibition 
of RANKL, RANKL in B and T cell differentiation, and 
RANKL involvement in dendritic cell survival), patients on 
concurrent immunosuppressive agents, with pre-existing 
immunosuppression, or who developed severe infection 
during therapy should undergo a complete evaluation of the 
benefits and risks of treatment prior to use of denosumab.19 
There are currently no reports of denosumab interfering with 
the metabolism of other compounds. However, it is wiser to 
avoid the concurrent use of immunosuppressants and immune 
modulators due to the possible increased risk of infection.
In addition, and in order to minimize further the already 
low risk of osteonecrosis of the jaw, patients scheduled to 
undergo invasive dental procedures, those with poor oral 
hygiene, those with malignancy and/or other additional 
systemic (glucocorticoids, chemotherapy) or local (radia-
tion, dental diseases) risk factors should either avoid or 
postpone administration of denosumab.19,81 In these patients, 
a comprehensive dental examination is mandatory prior to 
consideration of denosumab.
In conclusion, denosumab is a novel treatment option 
which can help the clinician to choose the right therapy for 
each osteoporotic patient. Although there are no established 
protocols by which to choose a particular drug, decisions 
regarding the onset, type, and duration of treatment are cur-
rently based on the need to reduce fracture risk. According to 
this approach and based on the properties of denosumab and 
its mode of action, it can be considered in: patients at high 
risk of fractures, particularly of the hip; patients who cannot 
tolerate oral bisphosphonates and are not willing to receive 
intravenous bisphosphonates; patients who do not want or 
are unable to follow complex dosing regimens; patients with 
renal insufficiency; and nursing home patients.82 However, 
denosumab can also be involved in sequential treatment 
plans of other patients based on the fact that pharmacologic 
treatment should not be static and must change over the 
patient’s lifetime to adapt the clinical and metabolic needs of 
each time period.83 In all cases, the clinician should keep in 
mind the reversibility of the effect of denosumab following 
discontinuation of treatment and act accordingly.
Conclusion
Osteoporosis is a major growing public health issue and 
represents the most common bone disease in humans. With 
the variety of antiosteoporotic compounds available as well 
as multiple novel therapies in advanced clinical trials, the 
trend of the therapeutic approach is towards individualized 
treatment. The properties of the ideal osteoporosis treatment 
include: antifracture efficacy at various skeletal sites, includ-
ing the spine, nonvertebral sites, and hip; a high skeletal 
and extraskeletal safety margin; mode of administration 
and treatment interval compatible with patient adherence; 
compatibility with concomitant treatment for other medical 
conditions; and affordable cost.81 Because denosumab seems 
to meet the above criteria to a satisfactory degree, it could 
be considered both as an effective alternative to previous 
bisphosphonate treatment as well as first-line treatment of 
newly diagnosed osteoporosis. Furthermore, it seems to 
be the treatment of choice in patients with some degree of 
kidney dysfunction.
The mode of action of denosumab is characterized by 
reversibility of its effect after treatment discontinuation, in 
contrast with bisphosphonates which are retained in the bone 
and exert a long-term antifracture effect.78 This could be a 
disadvantage, rendering a denosumab holiday prohibitive; 
on the other hand, it could be an advantage in patients at risk 
for oversuppression of bone turnover.
It appears that denosumab is reasonably safe for all 
subgroups of patients with postmenopausal osteoporosis, 
with the exception of those with hepatic or stage 5 renal 
insufficiency. However, given the lack of pharmacovigi-
lance data for this agent as yet and its brief post-marketing 
period, it would be prudent to be vigilant for adverse events 
related to the putative effect of RANKL inhibition in tissues 
other than bone, as well as those related to bone turnover 
oversuppression.
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